Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
No added benefit with pazopanib over ranibizumab for neovascular AMD

No added benefit with pazopanib over ranibizumab for neovascular AMD

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Preterm babies treated with bevacizumab for severe retinopathy of prematurity have lower motor scores

Preterm babies treated with bevacizumab for severe retinopathy of prematurity have lower motor scores

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Combination treatment improves outcomes in women with ovarian cancer

Combination treatment improves outcomes in women with ovarian cancer

Study: Cancer drug may help reduce bleeding in HHT patients

Study: Cancer drug may help reduce bleeding in HHT patients

Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Mathematical models of cancer behavior offer new insights on tumor growth

Mathematical models of cancer behavior offer new insights on tumor growth

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Two-drug combination before surgery benefits women with triple-negative breast cancer

Two-drug combination before surgery benefits women with triple-negative breast cancer

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Cancer-fighting cocktail shows promising results for advanced cervical cancer